Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer's Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab

被引：1
|
作者：
Melo, V. S. D. [1 ]
Rodrigues, C. A. [1 ]
Silva, I. A. [2 ]
机构：
[1] Ctr Hosp Medio Tejo, Psychiat, Tomar, Portugal
[2] Unidade Local Saude Norte Alentejano, Psychiat, Portalegre, Portugal
来源：
EUROPEAN PSYCHIATRY | 2023年 / 66卷
关键词：
D O I：
10.1192/j.eurpsy.2023.663
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPP0346
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [31] Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β-Amyloid
    Frisardi, V.
    Solfrizzi, V.
    Imbimbo, B. P.
    Capurso, C.
    D'Introno, A.
    Colacicco, A. M.
    Vendemiale, G.
    Seripa, D.
    Pilotto, A.
    Capurso, A.
    Panza, F.
    CURRENT ALZHEIMER RESEARCH, 2010, 7 (01) : 40 - 55
  • [32] The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease
    Ritchie, Craig W.
    Russ, Tom C.
    Banerjee, Sube
    Barber, Bob
    Boaden, Andrew
    Fox, Nick C.
    Holmes, Clive
    Isaacs, Jeremy D.
    Leroi, Ira
    Lovestone, Simon
    Norton, Matt
    O'Brien, John
    Pearson, Jim
    Perry, Richard
    Pickett, James
    Waldman, Adam D.
    Wong, Wai Lup
    Rossor, Martin N.
    Burns, Alistair
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [33] Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
    Todd E. Golde
    Neurotherapeutics, 2022, 19 : 209 - 227
  • [34] Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity
    Zhang, Yujie
    Chen, Jie
    Li, Yanru
    Jiao, Bin
    Luo, Shilin
    AGEING RESEARCH REVIEWS, 2025, 103
  • [35] Molecular Pathogenesis and Disease-modifying Therapies of Alzheimer's Disease and Related Disorders
    Iwatsubo, Takeshi
    JMA JOURNAL, 2022, 5 (03): : 307 - 313
  • [36] Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives
    Imbimbo, Bruno P.
    Lozupone, Madia
    Watling, Mark
    Panza, Francesco
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 919 - 933
  • [37] Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review
    Haddad, Hannah W.
    Malone, Garett W.
    Comardelle, Nicholas J.
    Degueure, Arielle E.
    Kaye, Adam M.
    Kaye, Alan D.
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (01):
  • [38] The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
    Craig W. Ritchie
    Tom C. Russ
    Sube Banerjee
    Bob Barber
    Andrew Boaden
    Nick C. Fox
    Clive Holmes
    Jeremy D. Isaacs
    Ira Leroi
    Simon Lovestone
    Matt Norton
    John O’Brien
    Jim Pearson
    Richard Perry
    James Pickett
    Adam D. Waldman
    Wai Lup Wong
    Martin N. Rossor
    Alistair Burns
    Alzheimer's Research & Therapy, 9
  • [39] Transthyretin as a therapeutic target: the future of disease-modifying therapies for Alzheimer’s disease
    Swetaleena Shaw
    Pratyush Porel
    Khadga Raj Aran
    Molecular Biology Reports, 2025, 52 (1)
  • [40] Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
    Henrik Zetterberg
    Barbara B. Bendlin
    Molecular Psychiatry, 2021, 26 : 296 - 308
12345